Furthermore, the in vivo subcutaneous tumor implantation model showed that intratumor injection of XY‐14 efficiently counteracted the stimulative effect of PCIF1 overexpression on tumor growth (Figure 4O–Q), highlighting the potential of targeting LPP3 with its inhibitor in RCC treatment. This evidence concerns the gene PCIF1 and renal cell carcinoma.